The Role of IL-12 in the Aetiology of SLE and its Connection to HBV Infection in Iraqi Patients
Introduction: Systemic lupus erythematosus (SLE) is a significant social and public health issue because the medications used to treat it can only manage the symptoms and halt the progression of the disease, not totally cure it. The purpose of this study is to determine the association between the blood level of IL-12 and SLE, as well as its consequences, such as lupus nephritis (LN), and its active or dormant condition, in Iraqi patients.
Method: The study enrolled 90 SLE patients from AL-Sadar teaching hospital, with 66(73.3%) developing lupus nephritis (LN) and 24(26.7%) without LN. Additionally, there were 60 (90.9%) and 6 (9.1) active patients. Only 48 of 90 individuals tested positive for HBsAg, whereas 42(46.6%) tested positive for HBV. Each participant donated 5 ml of blood for anti-dsDNA and IL-12 testing.
Results: In SLE patients with LN, IL-12 serum levels were considerably higher than in those without LN(p = 0.05). Different levels of IL-12 were found in the LN groups. Serum IL-12 concentrations were considerably lower in patients with HBV-associated SLE (3.41±0.85 pg/ml), non-HBV-associated SLE (2.05±0.66 pg/ml), and healthy controls (0.53±0.28 pg/ml). WBC count, ESR, anti-ds antibody, and ANA levels were all elevated in lupus patients and in the active groups.
Conclusion: Our research established that SLE patients have elevated IL-12 levels. IL-12 levels were significantly greater in SLE with LN as compared to SLE without LN, and they differed significantly between lupus nephritis classes II, IV, and V. Finally, significant differences in IL-12 levels were seen between HBV and non-HBV SLE patients.
How to cite this article:
Majeed AA, Hassan LA, Darweesh MF. The Role of IL-12 in the Aetiology of SLE and its Connection to HBV Infection in Iraqi Patients. J Commun Dis. 2022;54(1):41-46.
Barber MRW, Drenkard C, Falasinnu T, Hoi A, Mak A, Kow NY, Svenungsson E, Peterson J, Clarke AE, Ramsey-Goldman R. Global epidemiology of systemic lupus erythematosus. Nat Rev Rheumatol. 2021 Sep;17(9):515-32. [PubMed] [Google Scholar]
Ruchakorn N, Ngamjanyaporn P, Suangtamai T, Kafaksom T, Polpanumas C, Petpisit V, Pisitkun T, Pisitkun P.Performance of cytokine models in predicting SLE activity. Arthritis Res Ther. 2019 Dec;21(1):287. [PubMed] [Google Scholar]
Barcia‐Sixto L, Isenberg D. Systemic lupus erythematosus: causes and manifestations. Trends in Uro Men Heal. 2020 Jan;11(1):26-9. [Google Scholar]
ArnaudL, Tektonidou MG. Long-term outcomes in systemic lupus erythematosus: trends over time and major contributors. Rheumatology (Oxford). 2020 Dec;59(Suppl5):v29-38. [PubMed] [Google Scholar]
Anders HJ, Saxena R, Zhao MH, Parodis I, Salmon JE, Mohan C. Lupus nephritis. Nat Rev Dis Primers. 2020 Jan;6(1):7. [PubMed] [Google Scholar]
Howe HS, Leung BPL. Anti-cytokine autoantibodies in systemic lupus erythematosus. Cells. 2019 Dec;9(1):72.[PubMed] [Google Scholar]
Hamza T, Barnett JB, Li B. Interleukin 12 a key immuno regulatory cytokine in infection applications. Int J Mol Sci. 2010 Feb;11(3):789-806. [PubMed] [Google Scholar]
Zare A, Rashki A, Ghahari S, Ghayoori B.The analysis of correlation between IL-12 gene expression and hepatitis B virus in the affected patients. Virus disease. 2015 Sep;26(3):196-9. [PubMed] [Google Scholar]
Izmirly PM, Wan I, Sahl S, Buyon JP, Belmont HM, Salmon JE, Askanase A, Bathon JM, Geraldino-Pardilla L, Ali Y, Ginzler EM, Putterman C, Gordon C, Helmick CG, Parton H.The incidence and prevalence of systemic lupus erythematosus in New York County (Manhattan), New York: the Manhattan Lupus Surveillance Program. Arthritis Rheumatol. 2017 Oct;69(10):2006-17. [PubMed] [Google Scholar]
Nusbaum JS, Mirza I, Shum J, Freilich RW, Cohen RE, Pillinger MH, Izmirly PM, Buyon JP.P. Sex differences in systemic lupus erythematosus: epidemiology, clinical considerations, and disease pathogenesis. Mayo Clin Proc. 2020 Feb;95(2):384-94. [PubMed] [Google Scholar]
Petri M, Stojan G. Epidemiology of systemic lupus erythematosus: an update. Curr Opin Rheumatol. 2018 Mar;30(2):144-50. [PubMed] [Google Scholar]
Izmirly PM, Parton H, Wang L, McCune WJ, Lim SS, Drenkard C, Ferucci ED, Dall’Era M, Gordon C, Helmick CG, Somers EC. Prevalence of systemic lupus erythematosus in the United States: estimates from a meta-analysis of the Centers for Disease Control and Prevention National Lupus Registries. Arthritis Rheumatol. 2021 Jun;73(6):991-6. [PubMed] [Google Scholar]
Selvaraja M, Too CL, Tan LK, Koay BT, Abdullah M, Shah AM, Arip M, Amin-Nordin S.Elevated interleukin- 25 and its association to Th2 cytokines in systemic lupus erythematosus with lupus nephritis. PLoS One. 2019 Nov;14(11):e0224707. [PubMed] [Google Scholar]
Hahn BH, McMahon MA, Wilkinson A, Wallace WD, Daikh DI, Fitzgerald JD, Karpouzas GA, Merrill JT, Wallace DJ, Yazdany J, Ramsey-Goldman R, Singh K, Khalighi M, Choi SI, Gogia M, Kafaja S, Kamgar M, Lau C, Martin WJ, Parikh S, Peng J, Rastogi A, Chen W, Grossman JM; American College of Rheumatology.American College of Rheumatology guidelines for screening, case definition, treatment and management of lupus nephritis. Arthritis Care Res (Hoboken). 2012 Jun;64(6):797-808. [PubMed] [Google Scholar]
Mohammed SF, Abdalla MA, Ismaeil WM, Sheta MM. Serum leptin in systemic lupus erythematosus patients: its correlation with disease activity and some disease parameters. Egypt Rheumatol. 2018 Jan;40(1):23-7. [Google Scholar]
Banchereau R, Hong S, Cantarel B, Baldwin N, Baisch J, Edens M, Cepika AM, Acs P, Turner J, Anguiano E, Vinod P. Personalized immunomonitoring uncovers molecular networks that stratify lupus patients. Cell. 2016 Apr;165(3):551-65. [Google Scholar]
Tokano Y, Morimoto S, Kaneko H, Amano H, Nozawa K, Takasaki Y, Hashimoto H. Levels of IL‐12 in the sera of patients with systemic lupus erythematosus (SLE)-relation to Th1‐and Th2‐derived cytokines. Clin Exp Immunol. 1999 Apr;116(1):169-73. [PubMed] [Google Scholar]
Reynolds JA, McCarthy EM, Haque S, Ngamjanyaporn P, Sergeant JC, Lee E, Lee E, Kilfeather SA, Parker B, Bruce IN. Cytokine profiling in active and quiescent SLE reveals distinct patient sub populations. Arthritis Res Ther. 2018 Aug;20(1):173. [PubMed] [Google Scholar]
Larosa M, Zen M, Gatto M, Jesus D, Zanatta E, Iaccarino L, Inês L, Doria A. IL-12 and IL-23/Th17 axis in systemic lupus erythematosus. Exp Biol Med (Maywood). 2019 Jan;244(1):42-51. [PubMed] [Google Scholar]
Liu CC, Kao AH, Manzi S, Ahearn JM.Biomarkers in systemic lupus erythematosus: challenges and prospects for the future. Ther Adv Musculoskelet Dis. 2013 Aug;5(4):210-33. [PubMed] [Google Scholar]
Ma X, Nakayamada S, Kubo S, Sakata K, Yamagata K, Miyazaki Y, Yoshikawa M, Kitanaga Y, Zhang M, Tanaka Y. Expansion of T follicular helper-T helper 1 like cells through epigenetic regulation by signal transducer and activator of transcription factors. Ann Rheum Dis. 2018 Sep;77(9):1354-61. [PubMed] [Google Scholar]
Chen MH, Hsiao LT, Chen MH, Tsai CY, Huang YH, Chou CT.Clinical significance of chronic hepatitis B virus infection in patients with primary Sjogren’s syndrome. Clin Rheumatol. 2012 Feb;31(2):309-15. [PubMed] [Google Scholar]
Chen MH, Wu CS, Tsai C, Lee F, Huang Y. High risk of viral reactivation in hepatitis B patients with systemic lupus erythematosus. Int J Mol Sci. 2021 Aug;22(17):9116. [PubMed] [Google Scholar]
Li X, Liu X, Tian L, Chen Y. Cytokine-mediated immuno pathogenesis of hepatitis B virus infections. Clin Rev Allergy Immunol. 2016 Feb;50(1):41-54. [PubMed] [Google Scholar]
Copyright (c) 2022 Open Access
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.